Remdesivir production ramped up 10 times, says Mansukh Mandaviya

Taking to Twitter he said that the number of plants producing Remdesivir have also increased from just 20 to 60 within a month.

Remdesivir, coronavirus, covid-19, drugs, medicine, health
ANI General News
2 min read Last Updated : May 29 2021 | 2:54 PM IST

Minister of State for Chemical and Fertilizers Mansukh Mandaviya on Saturday said that the production of Remdesivir has been ramped up ten times from 33,000 vials per day to 3,50,000 vials per day.

Taking to Twitter he said that the number of plants producing Remdesivir have also increased from just 20 to 60 within a month.

"I am delighted and satisfied to inform you all that the Production of Remdesivir is ramped up ten times from just ~33,000 vials/day on 11th April 2021 to ~3,50,000 vials/day today under the astute leadership of Hon'ble PM Shri @narendramodi Ji," Mansukh Mandaviya said in a tweet.

He further said the government has decided to discontinue the central allocation of Remdesivir to states.

"We have also increased the number of plants producing Remdesivir from just 20 to 60 plants within a month. Now the country has enough #Remdesivir as the supply is much more than the demand. So we have decided to discontinue the Central Allocation of Remdesivir to states," he said.

The Union Minister said that the Centre has decided to procure 50 lakh vials of Remdesivir to maintain it as a strategic stock.

"But I have also directed @nppa_india & @CDSCO_INDIA_INF to continuously monitor the availability of Remdesivir in the country. Government of India has also decided to procure 50 lakh vials of Remdesivir to maintain it as a strategic stock for the emergency requirement," he added.

Meanwhile, with 1,73,790 fresh Covid-19 cases recorded in the last 24 hours, India on Saturday reported the lowest single-day Covid-19 rise in 45 days, maintaining the ongoing declining trend, according to the Union health ministry. Active cases in the country fell to 22,28,724 with active cases decreasing by 1,14,428 in the last 24 hours.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusRemdesivirCoronavirus Tests

First Published: May 29 2021 | 2:49 PM IST

Next Story